RxDoctor Payments Data

Robert Thaler, MD

Internal Medicine · Cincinnati, OHNPI 1073995635

Payments from drug & device makers

$6,572in general payments, 2019–2025

Across 348 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$970
  • AstraZeneca$790
  • Pfizer$628
  • Lilly USA, LLC$593
  • Novo Nordisk$447
  • Gilead$264
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,572 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$65,075
Medicare patients
158
Services billed
857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$66,666
EliquisApixaban55$55,943
MounjaroTirzepatide33$38,916
JardianceEmpagliflozin22$24,725
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,302
Soliqua 100-33Insulin Glargine/Lixisenatide11$12,114
Rosuvastatin Calcium118$2,215
Nifedipine ErNifedipine40$1,928
Atorvastatin Calcium226$1,798
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,586
Gabapentin61$1,102
Levothyroxine Sodium98$966
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$844
Metoprolol Succinate94$805
Lisinopril96$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$447$66,66638 claims
PfizerEliquis$628$55,94355 claims
Lilly USA, LLCMounjaro, Olanzapine$593$39,57545 claims
Boehringer IngelheimJardiance$238$24,72522 claims
GSKTrelegy Ellipta$254$15,30221 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$114$12,11411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$96698 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →